LU92348I2 - Virus West Nile inactivé, souche VM-2 et ses dérivés pharmaceutiquement acceptables (EQUIP WNV) - Google Patents
Virus West Nile inactivé, souche VM-2 et ses dérivés pharmaceutiquement acceptables (EQUIP WNV)Info
- Publication number
- LU92348I2 LU92348I2 LU92348C LU92348C LU92348I2 LU 92348 I2 LU92348 I2 LU 92348I2 LU 92348 C LU92348 C LU 92348C LU 92348 C LU92348 C LU 92348C LU 92348 I2 LU92348 I2 LU 92348I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- wnv
- equip
- strain
- pharmaceutically acceptable
- west nile
- Prior art date
Links
- 241000710886 West Nile virus Species 0.000 title 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30833401P | 2001-07-27 | 2001-07-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LU92348I2 true LU92348I2 (fr) | 2014-09-22 |
| LU92348I9 LU92348I9 (enExample) | 2019-01-02 |
Family
ID=27613166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92348C LU92348I2 (fr) | 2001-07-27 | 2014-01-06 | Virus West Nile inactivé, souche VM-2 et ses dérivés pharmaceutiquement acceptables (EQUIP WNV) |
Country Status (24)
| Country | Link |
|---|---|
| US (8) | US7153513B2 (enExample) |
| EP (3) | EP2281572A1 (enExample) |
| JP (2) | JP4718778B2 (enExample) |
| KR (2) | KR20090053967A (enExample) |
| CN (2) | CN1273189C (enExample) |
| AU (1) | AU2002365244B2 (enExample) |
| BE (1) | BE2014C006I2 (enExample) |
| BR (1) | BRPI0211492B1 (enExample) |
| CA (1) | CA2452545C (enExample) |
| CY (1) | CY2014010I2 (enExample) |
| DK (1) | DK1427444T3 (enExample) |
| ES (1) | ES2435095T3 (enExample) |
| FR (1) | FR14C0016I2 (enExample) |
| HR (1) | HRP20040195B1 (enExample) |
| HU (2) | HU228690B1 (enExample) |
| LU (1) | LU92348I2 (enExample) |
| ME (1) | ME00491B (enExample) |
| MX (1) | MXPA04000680A (enExample) |
| NZ (3) | NZ570270A (enExample) |
| PL (2) | PL212212B1 (enExample) |
| PT (1) | PT1427444E (enExample) |
| RS (1) | RS53184B (enExample) |
| WO (1) | WO2003061555A2 (enExample) |
| ZA (1) | ZA200401596B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7425437B2 (en) * | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
| HU228690B1 (en) * | 2001-07-27 | 2013-05-28 | Wyeth Corp | West nile vaccine |
| US7585621B2 (en) * | 2003-09-09 | 2009-09-08 | Idexx Laboratories, Inc. | Detection of West Nile virus infection and vaccination |
| US7074555B2 (en) * | 2004-04-28 | 2006-07-11 | Idexx Laboratories, Inc. | Detection of West Nile Virus |
| FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| WO2006029300A2 (en) | 2004-09-09 | 2006-03-16 | Research Development Foundation | Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
| WO2006107655A2 (en) * | 2005-04-01 | 2006-10-12 | Wyeth | Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference |
| US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| WO2006120230A2 (en) | 2005-05-12 | 2006-11-16 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| WO2006122964A1 (en) * | 2005-05-19 | 2006-11-23 | Crucell Holland B.V. | Methods for the production of a whole-inactivated west nile virus vaccine |
| EP1724338A1 (en) * | 2005-05-19 | 2006-11-22 | Crucell Holland B.V. | Methods for the production of a whole-inactivated West Nile Virus vaccine |
| CA2612047C (en) * | 2005-06-24 | 2015-05-12 | Intervet International B.V. | Inactivated chimeric vaccines and related methods of use |
| CN101563361B (zh) * | 2005-10-19 | 2014-01-29 | 佛罗里达大学研究基金公司 | 能够感染犬科动物的流感病毒及其用途 |
| EP1941033A2 (en) * | 2005-10-20 | 2008-07-09 | Wyeth a Corporation of the State of Delaware | Compositions and methods for the treatment of canine influenza virus disease |
| EP2026839A4 (en) * | 2005-12-14 | 2009-04-01 | Univ Oklahoma | RNA VIRUS VACCINE AND METHODS |
| CA2881717C (en) * | 2006-06-06 | 2018-06-12 | Cecilia Anna Wilhelmina Geuijen | Human binding molecules having killing activity against staphylococci and uses thereof |
| UA98812C2 (ru) | 2007-11-06 | 2012-06-25 | Вайет Ллк | Авирулентная активированная живая вакцина mycoplasma hyopneumoniae |
| WO2009143524A2 (en) | 2008-05-23 | 2009-11-26 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| US9642908B2 (en) * | 2008-07-30 | 2017-05-09 | University Of Kentucky Research Foundation | Equine disease model for herpesvirus neurologic disease and uses thereof |
| AU2009287449B2 (en) * | 2008-08-29 | 2015-04-30 | Boehringer Ingelheim Animal Health USA Inc. | West nile virus vaccine |
| EP2485725A2 (en) * | 2009-10-07 | 2012-08-15 | Wyeth LLC | Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof |
| BR112013023354B1 (pt) | 2011-03-14 | 2022-02-15 | Boehringer Ingelheim Animal Health Usa Inc | Composição imunogênica compreendendo cepas de vírus da rinite equina a (erav) e seu método de produção |
| CN103045544B (zh) * | 2011-10-17 | 2015-01-14 | 华中农业大学 | 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用 |
| SI3542819T1 (sl) * | 2013-05-14 | 2021-11-30 | Zoetis Services Llc | Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide |
| HK1224177A1 (zh) * | 2013-09-05 | 2017-08-18 | 硕腾服务有限责任公司 | Hendra和nipah病毒g糖蛋白免疫原性組合物 |
| US11033615B2 (en) | 2016-05-31 | 2021-06-15 | The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland | Zika virus vaccine and methods of production |
| PL70842Y1 (pl) * | 2017-08-25 | 2019-06-28 | Gondek Lukasz Kuznia Mocy | Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych |
| US12350328B2 (en) | 2019-02-27 | 2025-07-08 | University Of Rochester | Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (EIV) in horses |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US308334A (en) | 1884-11-18 | Ladder | ||
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US5741696A (en) * | 1992-08-07 | 1998-04-21 | Syntro Corporation | Recombinant equine herpesviruses |
| FR2702373B1 (fr) * | 1993-03-08 | 1996-06-07 | Rhone Merieux | Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable. |
| PT759780E (pt) * | 1994-05-10 | 2001-01-31 | American Home Prod | Vacina melhorada de vsrb vivo modificado |
| US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| IL139844A0 (en) | 1998-06-04 | 2002-02-10 | Us Gov Health & Human Serv | Nucleic acid vaccines for prevention of flavivirus infection |
| AU2002211490A1 (en) * | 2000-10-04 | 2002-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| WO2002068637A2 (en) | 2000-10-20 | 2002-09-06 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
| AU2002305028A1 (en) | 2001-02-28 | 2002-10-28 | Brown University Research Foundation | West nile virus epitopes and uses thereof |
| WO2002072036A2 (en) * | 2001-03-12 | 2002-09-19 | Yale University | Compositions and methods comprising west nile virus polypeptides |
| US20030104008A1 (en) * | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
| FR2823222B1 (fr) * | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
| HU228690B1 (en) * | 2001-07-27 | 2013-05-28 | Wyeth Corp | West nile vaccine |
| AU2003263853A1 (en) | 2002-08-16 | 2004-03-03 | Board Of Regents The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain iii antigens |
-
2002
- 2002-07-23 HU HU0401606A patent/HU228690B1/hu active Protection Beyond IP Right Term
- 2002-07-23 EP EP10183615A patent/EP2281572A1/en not_active Withdrawn
- 2002-07-23 RS YU8004A patent/RS53184B/sr unknown
- 2002-07-23 AU AU2002365244A patent/AU2002365244B2/en not_active Expired
- 2002-07-23 PT PT2806585T patent/PT1427444E/pt unknown
- 2002-07-23 BR BRPI0211492A patent/BRPI0211492B1/pt active IP Right Grant
- 2002-07-23 MX MXPA04000680A patent/MXPA04000680A/es active IP Right Grant
- 2002-07-23 CN CNB028146646A patent/CN1273189C/zh not_active Expired - Lifetime
- 2002-07-23 NZ NZ570270A patent/NZ570270A/en not_active Application Discontinuation
- 2002-07-23 WO PCT/US2002/023447 patent/WO2003061555A2/en not_active Ceased
- 2002-07-23 KR KR1020097010065A patent/KR20090053967A/ko not_active Ceased
- 2002-07-23 EP EP10183676A patent/EP2283858A3/en not_active Ceased
- 2002-07-23 ME MEP-2008-784A patent/ME00491B/me unknown
- 2002-07-23 DK DK02806585.2T patent/DK1427444T3/da active
- 2002-07-23 ES ES02806585T patent/ES2435095T3/es not_active Expired - Lifetime
- 2002-07-23 KR KR10-2004-7001202A patent/KR20040028952A/ko not_active Ceased
- 2002-07-23 JP JP2003561501A patent/JP4718778B2/ja not_active Expired - Lifetime
- 2002-07-23 CA CA2452545A patent/CA2452545C/en not_active Expired - Lifetime
- 2002-07-23 NZ NZ531265A patent/NZ531265A/en not_active IP Right Cessation
- 2002-07-23 CN CN2006101058113A patent/CN1935258B/zh not_active Expired - Lifetime
- 2002-07-23 EP EP02806585.2A patent/EP1427444B1/en not_active Expired - Lifetime
- 2002-07-23 HR HRP20040195AA patent/HRP20040195B1/hr not_active IP Right Cessation
- 2002-07-23 PL PL368535A patent/PL212212B1/pl unknown
- 2002-07-23 PL PL398575A patent/PL220846B1/pl unknown
- 2002-07-25 US US10/202,716 patent/US7153513B2/en not_active Expired - Lifetime
-
2004
- 2004-02-26 ZA ZA2004/01596A patent/ZA200401596B/en unknown
-
2006
- 2006-10-30 US US11/589,515 patent/US20070166324A1/en not_active Abandoned
- 2006-10-30 US US11/589,527 patent/US7445787B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,507 patent/US7648705B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,595 patent/US20070231350A1/en not_active Abandoned
- 2006-10-30 US US11/589,523 patent/US20070166326A1/en not_active Abandoned
- 2006-10-30 US US11/589,528 patent/US7648706B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,516 patent/US20070166325A1/en not_active Abandoned
-
2007
- 2007-02-13 NZ NZ553165A patent/NZ553165A/en not_active IP Right Cessation
-
2010
- 2010-11-15 JP JP2010255105A patent/JP2011057692A/ja active Pending
-
2013
- 2013-10-04 HU HUS1300055C patent/HUS1300055I1/hu unknown
-
2014
- 2014-01-06 LU LU92348C patent/LU92348I2/xx unknown
- 2014-01-31 BE BE2014C006C patent/BE2014C006I2/fr unknown
- 2014-02-20 CY CY2014010C patent/CY2014010I2/el unknown
- 2014-02-21 FR FR14C0016C patent/FR14C0016I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU92348I2 (fr) | Virus West Nile inactivé, souche VM-2 et ses dérivés pharmaceutiquement acceptables (EQUIP WNV) | |
| LU92024I2 (fr) | Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR) | |
| LU92381I2 (fr) | Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT) | |
| LU92513I2 (fr) | Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi) | |
| CY2016018I2 (el) | Εμβολιο κατα του ιου του δυτικου νειλου | |
| LU92419I2 (fr) | Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®) | |
| NO20035298D0 (no) | CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler | |
| NO20021719L (no) | 6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament | |
| CY1105963T1 (el) | Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης | |
| DK2298769T3 (da) | Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel | |
| NO20024238D0 (no) | Peptidase-spaltbare, målsökende antineoplastiske medikamenter, og deres terapautiske anvendelse | |
| ZA200603158B (en) | Immunogenic composition and method of developing a vaccine based on psoralen inactivated HIV | |
| LU92871I2 (fr) | Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera) | |
| NO20011503D0 (no) | Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler | |
| NO20030596D0 (no) | Benzimidazolderivater, deres fremstilling og terapeutiske anvendelse | |
| DK1095025T3 (da) | Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler | |
| DK1445252T3 (da) | Sulfonamid-derivater, deres fremstilling og anvendelse som medikamenter | |
| NO20023532D0 (no) | Dihydro-1,3,5-triazinaminderivater og deres terapeutiske anvendelser | |
| LU91251I2 (fr) | Vaccin à rotavirus (vivant) et ses dérivés pharmaceutiquement acceptables (ROTARIXr) | |
| NO20014270D0 (no) | Pyridopyranoazepinderivater, deres fremstilling og terapeutisk anvendelse | |
| NO20031838D0 (no) | Benzokazinonderivater, deres fremstilling og anvendelse | |
| NO20003773D0 (no) | Syklobutenderivater, deres fremstilling og deres terapeutiske anvendelser | |
| NO20040995L (no) | Subenhetsvaksine for smittsom bukspyttkjertel-nekrosevirus | |
| AU2002333773A1 (en) | New hepatitis c virus genotype, and its use as prophylactic, therapeutic and diagnostic agent | |
| NO20001781D0 (no) | 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse |